23andMe
dgmacarthur | November 11, 2009Medland et al. (2009). Common Variants in the Trichohyalin Gene Are Associated with Straight Hair in Europeans. The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2009.10.009
A couple of weeks ago I reported on a presentation by 23andMe's Nick Eriksson at the American Society of Human Genetics meeting in Honolulu, in which Eriksson presented data on a series of genome-wide association studies performed by the company using genetic and trait data from its customers.
Along with genetic analysis of a variety of other traits (such as asparagus anosmia and photic sneeze) Eriksson…
dgmacarthur | October 25, 2009It's been an intensive week of genomics here at the American Society of Human Genetics meeting, and I haven't been able to grab time to blog as much as I'd have liked. In fact there's a whole load of genomics news I'll be trying to cover in some detail over the next couple of weeks; for the moment, though, I couldn't let today's presentation from personal genomics company 23andMe go by without at least some comment. (For other coverage of the conference, do check out Luke Jostins' blog coverage and the stream of live analysis on Twitter.)
The 23andMe presenter (Nick Eriksson) delivered an…
dgmacarthur | October 14, 2009I'll be away for the American Society of Human Genetics meeting in Hawaii for most of the next couple of weeks - I'll be covering the conference primarily via Twitter, and you can follow all of the tweets from the conference using the #ASHG2009 hashtag.
Genetics bloggers/tweeters should also pencil in the "tweetup" on Thursday 22nd from 4:30 to 5:15 in the ASHG Press Office (Room 318 in the Convention Center), organised by Chris Gunter; anyone interested should RSVP via email. This should be a good chance to put faces to many of the names in your Twitter and RSS feeds.
There's a lot of…
dgmacarthur | October 13, 2009 Details are pretty sketchy, but a press release announced today suggests that personal genomics company 23andMe has performed a genome-wide association study comparing 100 current or former professional NFL players with a set of controls of unspecified sample size.
The shocking result:
The study did not find the tested players to be genetic outliers, suggesting that genetics may not be a good predictor of athletic success.
It's unsurprising that the results of this study are negative (more on this below), but the conclusions they draw from this are fallacious. In fact we know from twin and…
dgmacarthur | October 7, 2009Four scientists - including the omnipresent J. Craig Venter (left) - have penned an opinion piece in the latest issue of Nature based results from five individuals genotyped by two separate personal genomics companies. The article highlights some deficiencies in the way that genetic data are currently used by direct-to-consumer companies to generate risk predictions and to present them to customers.
The identity of the tested individuals isn't made explicit in the article, except to note that there were two males and two females from the same family and one unrelated female. All of the…
dgmacarthur | September 15, 2009Mark Henderson's interview with Anne Wojcicki, co-founder of personal genomics company 23andMe, is well worth a read. The big story is this: Wojcicki has floated the possibility of offering discounted genome scans to clinicians "to teach them to interpret genomic information that is now readily available to their patients".
Wojcicki explains:
"Clearly we need to engage with physicians to help them to understand this information," she said. "One of the things we've talked about is we'd love to get physicians comfortable with their own genomes first, have them understand what does it mean,…
dgmacarthur | September 15, 2009 In the second of three guest posts, lawyers Daniel Vorhaus and Lawrence Moore of the superb blog Genomics Law Report discuss the implications for personal genomics customers if their provider goes bankrupt. In part one of the series (posted yesterday), Vorhaus and Moore dissected the implications of the privacy policies of two personal genomics companies, TruGenetics and 23andMe.
Today's post is an in-depth analysis of the complex legal issues surrounding the treatment of genetic information gathered by a now-bankrupt personal genomics company. For those who get a little lost in the legal…
dgmacarthur | August 12, 2009A tweet from personal genomics company 23andMe (see screenshot below) sparked my interest:
I knew 23andMe had been successful in recruiting Parkinsons patients as part of its targeted drive, and the 337 unspecified "patients" are the product of their broader recruitment drive for diseased genomes, Research Revolution (which I've dissected in a previous post) - but the athletes were news to me.
A little Google-trawling revealed (see page 15 of this PDF article from Palo Alto Online) that 23andMe offered free genome scans to all of the participants in the currently ongoing Palo Alto Senior…
dgmacarthur | August 3, 2009Those interested in the commercial, technical or ethical issues around the emerging industry of personal genomics now have a chance to put their questions to the co-founder of 23andMe, Anne Wojcicki. The NY Times blog Freakonomics is inviting readers to add their questions to the comments section of this post; Wojcicki will respond in a later post.
The questions are already pouring in: one reader asks if Wojcicki believes that there is a genetic component to intelligence; another asks for advice on getting a tattoo made from his 23andMe raw data; another reader is looking for a job.
This is…
dgmacarthur | July 7, 2009Personal genomics company 23andMe has always differentiated itself from its more sober competitors through an emphasis on collaborative, consumer-driven research - essentially, encouraging its customers to contribute their genetic and trait data to internal research projects designed to find new genetic associations. It is widely believed that generating novel associations between genetic variants and traits is actually the core business strategy for the company, although the precise mechanism for converting such associations into cash-flow remains unclear.
The company's initial attempt at…
dgmacarthur | June 24, 2009Pharmacogenetics Reporter has a lengthy article (subscription required) on the California bill SB 482, sponsored by personal genomics company 23andMe, which seeks "to distinguish so-called "post-CLIA bioinformatics services" from entities providing laboratory services".
In other words, 23andMe is pushing to have companies purely providing analysis of genetic data regulated separately from those doing the actual laboratory testing. Since 23andMe out-sources its testing to an external laboratory, this would exempt the company from some regulatory requirements. The move follows some fairly…
dgmacarthur | June 16, 2009I've stumbled rather late across a very promising new blog on the experience of a consumer genomics customer, Fantastic Voyage. The blog is primarily written by Grant Wood, the senior IT strategist for a clinical genetics institute in Salt Lake City; the premise of the blog is that Wood will discuss his own experience of consumer genetic testing (via a 23andMe genome scan), while receiving input from two advisors: Marc Williams, a medical geneticist, and Janet Williams, a genetic counsellor.
In the two posts so far the highlights have been the insights from Marc Williams. For instance, on his…
dgmacarthur | June 11, 2009The buzz leading up to this week's Consumer Genetics Show in Boston suggested that a major announcement would be made by the CEO of genomics technology provider Illumina, Jay Flatley. Illumina provides the most popular second-generation sequencing instrument currently on the market, the Genome Analyzer II, and has been making noises about moving into the personal genomics industry since at least the beginning of the year, so the announcement itself was not exactly a shock: Illumina is launching a personal genome sequencing service.
The launch comes with a new website, the appealingly titled…
dgmacarthur | June 5, 2009A reader has pointed me to the latest issue of the American Journal of Bioethics, which is devoted to social networking and personal genomics. I'm still working my way through the many interesting articles, but for now I wanted to cover some useful points in the editorial (entitled "A Pragmatic Consideration of Ethical Issues Relating to Personal Genomics"), which was written by a series of big names from personal genomics company 23andMe, including both co-founders.
The article is designed to address some of the more popular misconceptions surrounding personal genomics; here's a quick run-…
dgmacarthur | April 27, 2009This seems like pretty interesting news:
23andMe, Inc., an industry leader in personal genetics, and Palomar Pomerado Health
(PPH), the largest public health district in California, today
announced that PPH will be offering the 23andMe Personal Genome Service
for sale to San Diegans at its outpatient health centers. As an
innovator in preventive health care, PPH encourages its communities to
understand their genetic information in order to make more informed
decisions about their health. This partnership marks the first time
that a healthcare organization has provided the Personal Genome…
dgmacarthur | April 19, 2009John Hawks riffs on the themes of a recent Economist article on personal genomics (which I've also talked about here).
Hawks argues that "nobody's quite figured out how to sell sequence to people" - that although 23andMe's marketing strategy is shrewd, it's still "marketing based on anxiety", and the provided content initially didn't seem that appealing:
I used to feel the way Altshuler does. What good could it possibly do to have my genes sequenced? I know the limits on the usefulness of the data. There's minimal medical value for most people right now. I'm not even sure what I would do…
dgmacarthur | April 7, 2009Attila Csordas has a post up at Partial Immortalization explaining how to use the application MitoWheel (which Csordas helped develop) to visualise data from the new Haplogroup Tree Mutation Mapper from 23andMe. This might be a fun way for genetic genealogy afficianados to spend a few minutes getting to know their genomes better.
This reminded me about a little experiment of Csordas' that I learnt about when I met him in Cambridge a couple of weeks ago, which strikes me as a quintessential expression of the spirit of the personal genomic era - posting his genetic data from 23andMe, one base…
dgmacarthur | April 1, 2009Personalised medicine pioneers Helix Health have announced their intention to seize control of the assets of personal genomics company 23andMe.
Helix Health founder Steve Murphy (left) laid out his takeover plans during a press conference this morning. "It's time to seize the moral high ground!!!!" he proclaimed, physically spelling out the additional exclamation marks to the assembled reporters. "23andMe have played their BS PR games for too long, and I'm here to put that right!"
During a four hour-long monologue that was often rambling and at times completely incoherent, pausing only for…
dgmacarthur | March 31, 2009Personal genomics company 23andMe has just launched an online community of "mommy bloggers" - a move I can only describe as sheer marketing genius.
I'll give you a moment to let the vision sink in. Imagine a group of women hungry for information about the best way to ensure the future health and wellbeing of their unborn children. Now imagine a website packed with sincere, caring mother-types - most of them well-established bloggers with a strong existing fan base - writing about the real day-to-day issues that mothers care about (in the words of one recruit: "momming, aging, and my twenty…
dgmacarthur | March 23, 2009To complete my 23andMe trifecta this morning, here's Steve Murphy frothing at the mouth about the company's recent antics:
Why is it so vital that physicians,
nurses and others in the healthcare field try to stay above the law?
Because patients lose trust in the system. They begin to think that
their care givers are reckless criminals. And WHO would trust their
life to a criminal???
Apparently,
this stream of thought doesn't even phase a company like 23andME. You
see, they are blatantly breaking the law in several states. Why? They
are on a mission. Destroy the current healthcare system,…